Nationwide, outbreak.info estimates that BA.2’s cumulative prevalence — which represents a ratio of sequences containing BA.2 to all sequences collected in the U.S. since the subvariant was first detected on Dec. 14, 2021 — is 1 percent.
Weekly estimates of BA.2 prevalence from the CDC suggest the subvariant accounted for 85.9 percent of COVID-19 cases in the week ending April 9, up from 75.4 percent in the week ending April 2.
Below is a breakdown of BA.2 prevalence by state and Washington, D.C., based on data from outbreak.info. As COVID-19 sequencing is not a random sample of mutations, the data represents outbreak.info’s best estimates of the subvariant’s prevalence, as opposed to true prevalence.
Note: Becker’s calculated each state’s estimated cumulative BA.2 presence using sequencing data from outbreak.info. Figures are rounded to the nearest hundredth.
|
State |
BA.2 positive samples |
Total sequences sampled |
Estimated cumulative prevalence (%) |
|
Rhode Island |
348 |
16,285 |
2.14 |
|
New Jersey |
715 |
58,726 |
1.22 |
|
Massachusetts |
1,470 |
156,179 |
0.94 |
|
New York |
1,550 |
168,839 |
0.92 |
|
Washington, D.C. |
97 |
10,589 |
0.92 |
|
Hawaii |
91 |
11,529 |
0.79 |
|
Connecticut |
300 |
38,721 |
0.77 |
|
Pennsylvania |
406 |
55,300 |
0.73 |
|
Vermont |
113 |
21,097 |
0.54 |
|
Maine |
78 |
16,590 |
0.47 |
|
Maryland |
249 |
53,827 |
0.46 |
|
New Hampshire |
51 |
11,699 |
0.44 |
|
Illinois |
290 |
70,386 |
0.41 |
|
Virginia |
191 |
48,695 |
0.39 |
|
Florida |
536 |
146,315 |
0.37 |
|
Washington |
352 |
97,095 |
0.36 |
|
Wisconsin |
155 |
56,326 |
0.28 |
|
Arizona |
250 |
98,238 |
0.25 |
|
Texas |
509 |
204,868 |
0.25 |
|
California |
1,248 |
528,781 |
0.24 |
|
Ohio |
96 |
46,362 |
0.21 |
|
Nevada |
68 |
33,438 |
0.2 |
|
Michigan |
143 |
70,773 |
0.2 |
|
North Carolina |
140 |
75,832 |
0.18 |
|
Delaware |
24 |
13,798 |
0.17 |
|
North Dakota |
27 |
15,685 |
0.17 |
|
Georgia |
88 |
53,431 |
0.16 |
|
Kentucky |
31 |
21,676 |
0.14 |
|
South Carolina |
31 |
22,027 |
0.14 |
|
Mississippi |
17 |
12,765 |
0.13 |
|
Utah |
105 |
85,159 |
0.12 |
|
Alaska |
14 |
11,626 |
0.12 |
|
Missouri |
30 |
25,894 |
0.12 |
|
Tennessee |
66 |
57,427 |
0.11 |
|
Louisiana |
31 |
28,042 |
0.11 |
|
Oregon |
42 |
44,707 |
0.09 |
|
Minnesota |
100 |
113,058 |
0.09 |
|
Indiana |
29 |
36,972 |
0.08 |
|
Colorado |
141 |
189,972 |
0.07 |
|
Nebraska |
16 |
21,886 |
0.07 |
|
Idaho |
15 |
21,792 |
0.07 |
|
Kansas |
11 |
19,370 |
0.06 |
|
Oklahoma |
3 |
5,349 |
0.06 |
|
West Virginia |
14 |
27,193 |
0.05 |
|
Arkansas |
8 |
16,006 |
0.05 |
|
Alabama |
8 |
17,283 |
0.05 |
|
Iowa |
7 |
17,171 |
0.04 |
|
Wyoming |
7 |
34,039 |
0.02 |
|
Montana |
2 |
15,926 |
0.01 |
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
